Is mRNA technology the right fit for flu shots? Experts aren't so sure
Experts see some significant benefits of applying mRNA technology to the production of flu vaccine — but also some serious challenges.
Stay updated with breaking news from Sanofi Pasteur. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts see some significant benefits of applying mRNA technology to the production of flu vaccine — but also some serious challenges.
Project headed by Oxford University’s Professor Teresa Lambe OBE (Calleva Head of Vaccinology and Immunology, Department of Paediatrics) and co-developer of the Oxford/AstraZeneca COVID-19 vaccine and Paul Klenerman (Sidney Truelove Professor, Nuff
/PRNewswire/ -- AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced...
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
/PRNewswire/ -- The "Global Recombinant DNA Technology Market Analysis & Forecast to 2023-2033: Market By Product; By End User; and By Region" report has been...